BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huang VW, Chang HJ, Kroeker KI, Goodman KJ, Hegadoren KM, Dieleman LA, Fedorak RN. Management of Inflammatory Bowel Disease during Pregnancy and Breastfeeding Varies Widely: A Need for Further Education. Can J Gastroenterol Hepatol 2016;2016:6193275. [PMID: 27725926 DOI: 10.1155/2016/6193275] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Meng X, Dunsmore G, Koleva P, Elloumi Y, Wu RY, Sutton RT, Ambrosio L, Hotte N, Nguyen V, Madsen KL, Dieleman LA, Chen H, Huang V, Elahi S. The Profile of Human Milk Metabolome, Cytokines, and Antibodies in Inflammatory Bowel Diseases Versus Healthy Mothers, and Potential Impact on the Newborn. J Crohns Colitis 2019;13:431-41. [PMID: 30418545 DOI: 10.1093/ecco-jcc/jjy186] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
2 Silva EFC, Baima JP, de Barros JR, Renosto FL, de Sibia CF, Saad-Hossne R, Sassaki LY. Anti-TNF Exposure during Pregnancy in Crohn's Disease Patients. Case Rep Gastroenterol 2018;12:608-16. [PMID: 30483038 DOI: 10.1159/000493921] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Kushner CJ, Concha JSS, Werth VP. Treatment of Autoimmune Bullous Disorders in Pregnancy. Am J Clin Dermatol 2018;19:391-403. [DOI: 10.1007/s40257-018-0342-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
4 Jahnsen JA, Widnes SF, Schjøtt J. Analysis of questions about use of drugs in breastfeeding to Norwegian drug information centres. Int Breastfeed J 2018;13:1. [PMID: 29339968 DOI: 10.1186/s13006-017-0143-8] [Cited by in Crossref: 6] [Article Influence: 1.5] [Reference Citation Analysis]
5 Baer PA, Aumais G, Ewara EM, Khraishi M, Marrache AM, Panaccione R, Wade JP, Marshall JK. Patterns and predictors of long-term retention of inflammatory bowel or rheumatoid disease patients on innovator infliximab: an analysis of a Canadian prescriptions claims database. Patient Prefer Adherence 2018;12:1805-14. [PMID: 30271124 DOI: 10.2147/PPA.S171363] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Sator P. Safety and tolerability of adalimumab for the treatment of psoriasis: a review summarizing 15 years of real-life experience. Ther Adv Chronic Dis 2018;9:147-58. [PMID: 30065812 DOI: 10.1177/2040622318772705] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
7 Singh S, Picardo S, Seow CH. Management of Inflammatory Bowel Diseases in Special Populations: Obese, Old, or Obstetric. Clin Gastroenterol Hepatol 2020;18:1367-80. [PMID: 31712084 DOI: 10.1016/j.cgh.2019.11.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
8 Szymańska E, Kisielewski R, Kierkuś J. Reproduction and Pregnancy in Inflammatory Bowel Disease - Management and Treatment Based on Current Guidelines. J Gynecol Obstet Hum Reprod 2021;50:101777. [PMID: 32315763 DOI: 10.1016/j.jogoh.2020.101777] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Picardo S, Seow CH. A Pharmacological Approach to Managing Inflammatory Bowel Disease During Conception, Pregnancy and Breastfeeding: Biologic and Oral Small Molecule Therapy. Drugs 2019;79:1053-63. [PMID: 31183768 DOI: 10.1007/s40265-019-01141-w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]